These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
100 related articles for article (PubMed ID: 18669476)
1. Drug development in the targeted therapy era. Paoletti P J Clin Oncol; 2008 Aug; 26(22):3815-6. PubMed ID: 18669476 [No Abstract] [Full Text] [Related]
2. Patient-reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer. Welslau M; Diéras V; Sohn JH; Hurvitz SA; Lalla D; Fang L; Althaus B; Guardino E; Miles D Cancer; 2014 Mar; 120(5):642-51. PubMed ID: 24222194 [TBL] [Abstract][Full Text] [Related]
3. Metastatic breast cancer treated with lapatinib with a prolonged benefit: a case report and a review of therapeutic options available. Bianchi GV; Duca M; Sica L; Mariani G Tumori; 2013; 99(6):269e-72e. PubMed ID: 24503801 [TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer. Saura C; Garcia-Saenz JA; Xu B; Harb W; Moroose R; Pluard T; Cortés J; Kiger C; Germa C; Wang K; Martin M; Baselga J; Kim SB J Clin Oncol; 2014 Nov; 32(32):3626-33. PubMed ID: 25287822 [TBL] [Abstract][Full Text] [Related]
5. Can early response assessment guide neoadjuvant chemotherapy in early-stage breast cancer? Esteva FJ; Hortobagyi GN J Natl Cancer Inst; 2008 Apr; 100(8):521-3. PubMed ID: 18398093 [No Abstract] [Full Text] [Related]
6. Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancer. Gajria D; Gonzalez J; Feigin K; Patil S; Chen C; Theodoulou M; Drullinsky P; D'Andrea G; Lake D; Norton L; Hudis CA; Traina TA Breast Cancer Res Treat; 2012 Jan; 131(1):111-6. PubMed ID: 21898114 [TBL] [Abstract][Full Text] [Related]
7. CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer. Pivot X; Manikhas A; Żurawski B; Chmielowska E; Karaszewska B; Allerton R; Chan S; Fabi A; Bidoli P; Gori S; Ciruelos E; Dank M; Hornyak L; Margolin S; Nusch A; Parikh R; Nagi F; DeSilvio M; Santillana S; Swaby RF; Semiglazov V J Clin Oncol; 2015 May; 33(14):1564-73. PubMed ID: 25605838 [TBL] [Abstract][Full Text] [Related]
8. Lapatinib and metronomic capecitabine combination in an HER2-positive inflammatory breast cancer patient: a case report. Montagna E; Cancello G; Torrisi R; Rizzo S; Scarano E; Colleoni M Ann Oncol; 2010 Mar; 21(3):667-668. PubMed ID: 20032127 [No Abstract] [Full Text] [Related]
9. [Docetaxel (Taxotere) in combination with anthracycline, capecitabin (Xeloda) and new drugs]. Galligioni E Tumori; 2001; 87(1 Suppl 2):S1-9. PubMed ID: 11357871 [No Abstract] [Full Text] [Related]
10. Efficacy of capecitabine monotherapy as the first-line treatment of metastatic HER2-negative breast cancer. Babacan T; Efe O; Hasirci AS; Demirci F; Buyukhatipoglu H; Balakan O; Sarici F; Kertmen N; Esin E; Akin S; Ates O; Aksoy S; Sever AR; Altundag K Tumori; 2015; 101(4):418-23. PubMed ID: 25953439 [TBL] [Abstract][Full Text] [Related]
11. A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer. Martin M; Bonneterre J; Geyer CE; Ito Y; Ro J; Lang I; Kim SB; Germa C; Vermette J; Wang K; Wang K; Awada A Eur J Cancer; 2013 Dec; 49(18):3763-72. PubMed ID: 23953056 [TBL] [Abstract][Full Text] [Related]
12. Over 17-month complete clinical brain response with a well-tolerated lapatinib plus capecitabine combination in a very young patient afflicted by HER2-positive metastatic breast cancer. Sini V; Menghi A; Cursano MC; Mandolini PL; Lanza R Tumori; 2013; 99(6):273e-7e. PubMed ID: 24503802 [TBL] [Abstract][Full Text] [Related]
13. Ten years of HER2-directed therapy: still questions after all these years. Krop IE; Winer EP Breast Cancer Res Treat; 2009 Jan; 113(2):207-9. PubMed ID: 18463974 [No Abstract] [Full Text] [Related]
14. Complete response of brain metastases from breast cancer overexpressing Her-2/neu to radiation and concurrent Lapatinib and Capecitabine. Abboud M; Saghir NS; Salame J; Geara FB Breast J; 2010; 16(6):644-6. PubMed ID: 21070441 [TBL] [Abstract][Full Text] [Related]
15. Lapatinib plus capecitabine for HER2-positive advanced breast cancer: a multicentre study of Anatolian Society of Medical Oncology (ASMO). Cetin B; Benekli M; Turker I; Koral L; Ulas A; Dane F; Oksuzoglu B; Kaplan MA; Koca D; Boruban C; Yilmaz B; Sevinc A; Berk V; Uncu D; Harputluoglu H; Coskun U; Buyukberber S J Chemother; 2014 Oct; 26(5):300-5. PubMed ID: 24112786 [TBL] [Abstract][Full Text] [Related]
16. Lapatinib plus capecitabine in patients with HER2-positive advanced breast cancer. Cameron D Clin Adv Hematol Oncol; 2007 Jun; 5(6):456-8. PubMed ID: 17679920 [No Abstract] [Full Text] [Related]
17. 18FDG-PET for early prediction of complete response to lapatinib and capecitabine in HER2-positive metastatic breast cancer: a case report. Riccardi F; Mocerino C; Barbato C; Vitale MG; Carrillo G; Trunfio M; Minelli S; Cartenì G Tumori; 2013; 99(6):257e-60e. PubMed ID: 24503798 [TBL] [Abstract][Full Text] [Related]
18. Phase II trial of fulvestrant with metronomic capecitabine for postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer. Schwartzberg LS; Wang G; Somer BG; Blakely LJ; Wheeler BM; Walker MS; Stepanski EJ; Houts AC Clin Breast Cancer; 2014 Feb; 14(1):13-9. PubMed ID: 24268206 [TBL] [Abstract][Full Text] [Related]
19. Rapid tumor shrinkage with lapatinib plus capecitabine in a patient with massive liver involvement. Giotta F; Latorre A; Cramarossa A; Simone G; Florio C; Oliva S; Lorusso V Tumori; 2013; 99(6):278e-81e. PubMed ID: 24503803 [TBL] [Abstract][Full Text] [Related]
20. Erlotinib in combination with capecitabine and docetaxel in patients with metastatic breast cancer: a dose-escalation study. Twelves C; Trigo JM; Jones R; De Rosa F; Rakhit A; Fettner S; Wright T; Baselga J Eur J Cancer; 2008 Feb; 44(3):419-26. PubMed ID: 18249110 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]